1) Imagine that you are trying to administer a drug to a patient with a mutation in a carrier protein that renders him/her unable to absorb the drug from the GI tract. If you need to use a drug of this sort in such a patient, how can you do it effectively?
2) Warfarin needs to be used in a patient with a mutation that reduces warfarin metabolism. Can this be done safely and if so, how?
3)As mentioned in the presentation, some patients have a genetically enhanced sensitivity to warfarin. Can you think of a mechanism that could explain this effect? Explain if this effect is pharmacokinetic, pharmacodynamic or neither.